Purpose: To investigate the utility of an advanced magnetic resonance spectroscopy (MRS) protocol in the clinical setting, and to compare the localization accuracy, spectral quality, and quantification repeatability between this advanced and the conventional vendor-provided MRS protocol on a clinical 3T platform. Methods: Proton spectra were measured from the posterior cingulate cortices in 30 healthy elderly subjects by clinical MR technologists using a vendor-provided (point resolved spectroscopy with advanced 3D gradient-echo B 0 shimming) and an advanced (semi-LASER with FAST(EST)MAP shimming) protocol, in random order. Spectra were quantified with LCModel using standard pipelines for the clinical and research settings, respectively. Results: The advanced protocol outperformed the vendorprovided protocol in localization accuracy (chemical-shift-displacement error: 2.0%/ppm, semi-LASER versus 11.6%/ppm, point resolved spectroscopy), spectral quality (water linewidth: 6.1 6 1.8 Hz, FAST(EST)MAP versus 10.5 6 3.7 Hz, 3D gradient echo; P < 7e-6; residual water: 0.08 6 0.12%, VAPOR versus 0.45 6 0.50%, WET; P < 2e-5) and within-session repeatability of metabolite concentrations, particularly of low signal-tonoise ratio data with two to eight averages (test-retest coefficients of variance of metabolite concentrations, P < 0.01). Concentrations of J-coupled metabolites such as gaminobutyric acid and glutamate were biased when using the default pipeline with simulated macromolecules. Conclusions: The quality of MRS data can be improved using advanced acquisition and analysis protocols on standard 3T hardware in the clinical setting, which can facilitate robust applications in central nervous system diseases. Magn
INTRODUCTION
Proton magnetic resonance spectroscopy ( 1 H MRS) provides a wealth of biochemical and metabolic information complementary to conventional structural MRI, as it enables noninvasive and regional quantification of endogenous neurochemicals. The international MRS Consensus Group has recently documented the clinical utility of MRS for diagnostic and prognostic purposes in common disorders of the central nervous system (1) . The group also emphasized that a lack of quality assurance is a current impediment to widespread diagnostic and prognostic use in the clinical setting. Thus, the compromised data quality obtained with standard clinical MRS packages may result in poor reproducibility of neurochemical concentrations, thereby limiting clinical utility. Meanwhile, an increasing volume of high-quality MRS data is being generated in the research setting from centers that specialize in MR methods development, as well as at sites that obtain advanced MRS protocols via customerto-customer sequence transfer agreements. However, the feasibility of using such advanced MRS protocols, including nonstandard adjustments such as voxel-based B 0 and B 1 calibrations (2,3), has not been evaluated in the clinical setting. Furthermore, the potential benefits of using an advanced MRS protocol over a conventional protocol for data quality have not been evaluated systematically by parallel acquisitions in the same MR session.
For clinical 1 H MRS, stimulated echo acquisition mode (STEAM) (4) and point resolved spectroscopy (PRESS) (5) are the standard pulse sequences provided in commercial MRS packages. Although STEAM provides good localization due to high bandwidth of the 90 pulses, requires low radiofrequency (RF) power, and allows ultrashort echo time (TE), it produces only half the signal compared with a spin-echo sequence. In comparison, PRESS retains full signal intensity and achieves relatively short TE (30 ms). However, because of increased spectral dispersion at 3 T and above, chemical shift displacement error (CSDE) becomes unacceptable with PRESS (6) .
In contrast, several highly optimized pulse sequences, such as STEAM, SPECIAL and semi-LASER (sLASER), have been used to generate high-quality MRS data from healthy and diseased brain in the research setting (3, (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . Of these, the sLASER sequence (13, 14) provides single-shot full-intensity signal with clean localization and minimal CSDE as a result of high bandwidth adiabatic full-passage (AFP) pulses. Pairs of AFP pulses in sLASER further suppress J-evolution and prolong apparent transverse relaxation times (T 2 ) (18) . When combined with voxel-based B 0 and B 1 calibration routines, sLASER was shown to provide neurochemical profiles with high within- (2) and between-site reproducibility at 3 and 7 T (3, 12) . Of note, five major metabolites (N-acetylaspartate (NAA), total creatine (tCr), total choline (tCho), glutamate (Glu), and myo-inositol (Ins)) were quantified with a test-retest coefficient of variance (CV) 5% from spectra averaged over 5 min (2) .
Therefore, we chose to compare the vendor-provided full-intensity MRS protocol using the PRESS sequence with an advanced protocol that uses the sLASER sequence (14) that has been validated for within-and between-site reproducibility (3, 12) . The aim of the study was to (i) evaluate the feasibility of executing an advanced MRS protocol in the clinical setting with rotating MR technologists, and (ii) compare the spectral quality and quantification precision between the standard vendor-provided and the advanced protocols on a 3T scanner. We studied the posterior cingulate cortex (PCC) in a healthy elderly cohort, because of its role in agerelated neurodegenerative diseases such as Alzheimer's disease. Moreover, the technologists who participated in the study were well-trained to position this voxel based on anatomical landmarks. Finally, the healthy elderly population presented a clinically relevant cohort with smaller brain volumes than a young cohort, and associated challenges for MRS such as compromised signal-to-noise ratio (SNR).
METHODS

Subjects
Clinically normal elderly participants (n 5 30; 15 males, age 5 80 6 5 years) were recruited from the Mayo Clinic Study of Aging (19) and enrolled after giving informed consent approved by the institutional review board. Participants were excluded if they had cognitive impairment or abnormal MRI findings, such as traumatic brain injury, intracranial tumor, large hemispheric infarct, epilepsy, or normal pressure hydrocephalus.
Magnetic Resonance Acquisitions
Data were acquired on a 3T clinical Verio Siemens scanner (Siemens Medical Solutions, Erlangen, Germany) running syngo VB17A at the Mayo Clinic Rochester by three rotating neuroradiology MR technologists. The technologists had at least 10 years of experience in the MR field (both in MRI and MRS acquisitions on GE and Siemens scanners). Each technologist followed detailed written instructions on how to run the randomized MRS acquisition protocols (Fig. 1) . In addition, the first three ) were acquired to select a volume of interest (VOI) of 8 mL in PCC. The anterior-inferior corner of the VOI was placed at the splenium of the corpus callosum, and the anterior-superior corner was below the cingulate sulcus (Fig. 2) . This VOI partially includes posterior cingulate gyri and precunei (portions of Brodmann areas 23 and 31). In the same session, single-voxel proton spectra were acquired using the vendor-provided and advanced protocols, as described subsequently, in a randomized order in each subject (Fig. 1) .
Vendor-Provided MRS Protocol
The conventional protocol consisted of a PRESS sequence (TR/TE 5 5000/30 ms) that uses the water suppression enhanced through T 1 effects (WET) for water suppression (WS). The protocol was executed according to vendor-provided instructions. Specifically, the system B 1 RF field (i.e., reference voltage) was determined at the start of the study (i.e., during the prescan calibration), and the WS flip angle was adjusted by the system before the MRS acquisition. B 0 shimming was automatically carried out using the system's advanced 3D gradientecho (GRE) shim. No manual shim adjustments were done by the technologists.
PRESS spectra were acquired with 64 averages, 70-Hz WS bandwidth, 2048 complex data points, and a spectral width of 2.5 kHz (the highest possible bandwidth currently available in the vendor's sequence). Waterreference spectra were acquired for eddy-current correction and metabolite quantification (3).
De-identified raw MRS data were transferred from the Mayo Clinic to the University of Minnesota for metabolite quantification. According to standard practice for clinical MRS, eddy current-corrected, summed PRESS spectra were used for metabolite quantification (20) . Metabolites were quantified with LCModel 6.3-0G (21) with the water-scaling option (22, 23) . To enable a direct comparison of metabolite concentrations obtained with the conventional and advanced protocols, basis sets for both protocols were simulated based on density-matrix formalism using the same chemical shifts and J-coupling values (24, 25) . To account for the large CSDE in PRESS, full 3D localized simulations (40 3 40 3 40 spatial points (26)) were performed with RF pulse shapes and TE timings used in vivo. Nineteen basis spectra were generated: alanine, ascorbate, aspartate, creatine (Cr), caminobutyric acid (GABA), glucose, Glu, glutamine (Gln), glutathione (GSH), glycerophosphorylcholine (GPC), Ins, scyllo-inositol (sIns), lactate, NAA, N-acetylaspartylglutamate (NAAG), phosphocreatine (PCr), phosphocholine, phosphorylethanolamine, and taurine. According to standard practice for LCModel fitting of clinical MRS spectra, mathematically estimated macromolecule (MM) and lipid signals within LCModel (i.e., setting NSIMUL 5 11) and other LCModel parameters at their standard default values were used for the analysis of PRESS spectra.
Advanced MRS Protocol
The advanced protocol used the sLASER sequence (TR/ TE 5 5000/28 ms), as described previously (3, 14) . Water suppression was achieved with the VAPOR technique, interleaved with outer volume suppression pulses (27) . This sLASER sequence (14) is currently available as a work-in-progress package in select versions of the Siemens software. B 0 shimming inside the VOI was carried out using the adiabatic version of FAST(EST)MAP (FM) (28) . Although FM is available as a work-in-progress package on Siemens (No. 577 on syngo VB17A), it is not routinely used in the clinical setting.
The FM shim protocol (TR/TE 5 2000/56 ms, bar thickness 5 5 mm, readout field of view 5 300 mm) was performed in four iterations: the first-order shims were first corrected based on the linear three-projection maps (evolution time, s 5 5 ms in echo-planar-imaging (EPI) mode), followed by adjustment of second-order terms twice where the fields were mapped along six projections (s 5 5 ms in EPI mode), and finally the firstorder shims were compensated again using linear six projection maps (s 5 10 ms in non-EPI mode). The total adjustment time was within 100 s, comparable to the system advanced 3D-GRE shim routine with three iterations. No manual shim adjustments were performed. The RF power for the 90 asymmetric pulse and the WS pulses were calibrated in the selected VOI (3).
sLASER spectra were acquired with 64 averages, 70-Hz WS bandwidth, 2048 complex points, and a spectral width of 6 kHz (14). Nonsuppressed water scans were also obtained for eddy current correction and quantification. In addition, fully relaxed unsuppressed water signals were acquired at 12 TEs, ranging from 28 to 4000 ms, to determine the cerebrospinal fluid (CSF) content and T 2 of tissue water in the selected VOI (29) .
After transfer of the de-identified raw MRS data to the University of Minnesota, single-shot sLASER spectra were processed in MATLAB (20) according to a previously described protocol (2, 3, 30, 31) , namely, single shots were eddy-current, frequency, and phase corrected before summation.
sLASER spectra were quantified with LCModel 6.3-0G (21) with the water-scaling option (22,23) using 19 basis spectra, mentioned previously, which were generated using nonlocalized density-matrix simulation with actual RF shapes and timings as a result of the minimal CSDE in sLASER (2%/ppm for AFP pulses). In addition, an experimentally measured MM spectrum (obtained using the inversion-recovery technique in four healthy subjects: 928 averages and TR/inversion time 5 2.5/0.75 s) (3) was used together with optimized LCModel parameters as described previously (2, 3, 12, 14, 27, (31) (32) (33) (34) (35) (36) . Briefly, the fit was performed between 0.5 to 4.2 ppm, the zero and first-order phases were fixed at zero (as phase correction between spectra is performed on the spectra during postprocessing, before LCModel), the convolution parameter relative full-width half maximum was set to 2.5, and the knot spacing of the spline baseline (i.e., DKNTMN) was set to 0.25. To account for the falx cerebri lipid signal (37) observed in several of the elderly subjects, a singlet peak was simulated at 1.45 ppm within LCModel to fit the sLASER data.
Final Concentrations
Metabolite concentrations from PRESS and sLASER were corrected for T 2 relaxation of tissue water, CSF content, and assuming 82% tissue-water content (38), as described previously (3) . A water T 2 of 100 ms was used with sLASER; this value represents the mean T 2 from all subjects obtained by fitting the integrals of the unsuppressed water acquired at different TEs with a biexponential fit with the T 2 of CSF fixed at 740 ms and assuming that the apparent T 2 of water under CarrPurcell conditions is 1.5 times that of the measured free precession T 2 (3). For PRESS, a water T 2 of 80 ms was used (39) . Signal loss as a result of T 2 relaxation of metabolites was neglected, as the apparent T 2 is dependent on the sequence, as well as individual metabolites.
Only metabolites quantified with Cram er-Rao lower bounds (CRLBs) less than or equal to 50% from at least half of the spectra were included in the neurochemical profiles. If the correlation coefficient between two metabolites was less than 20.7 in most spectra, then only their sum was reported (e.g., tCr 5 Cr 1 PCr and tCho 5 GPC 1 PC).
Repeatability
To evaluate the repeatability of metabolite quantification with the two MRS protocols at varying SNR levels, we analyzed the test-retest CV of metabolite concentrations (standard deviation divided by mean concentration) obtained from the subspectra (i.e., sums of every 2, 4, 8, 16, and 32 consecutive shots for all spectra). All resulting subspectra were analyzed with LCModel as described previously for the conventional and advanced MRS protocols. The repeatability CV was then calculated by taking the mean of the intrasubject CVs across all subjects at each SNR level.
Statistical Analysis
Water linewidth and suppression efficiency from the two MRS protocols were compared using the Wilcoxon signed-rank test because of the skewness of these data. Concentrations and repeatability CV between the MRS protocols were compared using paired t-tests.
RESULTS
Feasibility, Spectral Pattern, Quality, CSDE, and RF Voltage
All three MR technologists were able to successfully run the advanced spectroscopy protocol, including sLASER and FM shimming, after an average of three supervised sessions. A similar spectral pattern was observed between the conventional and advanced MRS protocols, whereas lines were typically broader with the conventional protocol (Fig. 2) .
For a visual assessment of reproducibility of spectral quality among subjects, the spectra from all subjects with each protocol were overlaid (Fig. 3) . Metabolite spectra were clearly visible when spectra were scaled by the residual water peak in sLASER data in all subjects without apparent baseline artifacts. In comparison, baseline distortions were observed downfield from 3.5 ppm in the PRESS data as a result of a large residual water signal. The falx cerebri lipid peak (37) at 1.45 ppm, present in some subjects, was observed in both protocols. In the 1 to 2 ppm spectral window, a higher incidence of unwanted coherences was apparent in PRESS data relative to sLASER data.
The refocusing pulses in PRESS resulted in 11.6%/ ppm CSDE, translating to approximately 30% CSDE between the two edges of the spectrum (over a 2.6 ppm range), compared with 2.0%/ppm in sLASER, as depicted by the extent of the VOI displacements in Figure 2 .
To evaluate the accuracy of the RF power used with the conventional protocol (based on the slice-based prescan calibration), we compared the system-found RF power level, as given by the transmitter reference voltage, to that obtained for the selected VOI during sLASER calibration. The RF levels were identical in 16 of 30 subjects between the conventional PRESS and the advanced sLASER protocols (Supporting Fig. S1) . However, this level was underestimated in 10 subjects and overestimated in 4 subjects with the system calibration relative to the VOI-based B 1 level measured with sLASER in the same subjects (Supporting Fig. S1 ).
B 0 Shimming and WS Efficiency
For a quantitative assessment of spectral quality, spectral linewidths and water residual signal were evaluated with each protocol. Linewidths were consistently broader with the conventional protocol using the system advanced 3D shim (10.5 6 3.7 Hz) than with advanced protocol with FM shim (6.1 6 1.8 Hz, Fig. 4a ). Seventeen of 30 subjects had a water linewidth of more than 10 Hz with the conventional protocol compared with only one subject with the advanced protocol, a linewidth criterion previously used for exclusion of spectra at 3 T (3).
Better WS performance was achieved with VAPOR in the advanced protocol compared with WET in the conventional protocol; negligible residual water was observed with VAPOR (0.08 6 0.12%) compared with WET (0.45 6 0.50%, Fig. 4b) . Similarly, the ratio of residual water to tCr-CH 3 was higher in the conventional protocol by approximately 10 times on average than the advanced protocol (Fig. 4c) .
Concentrations With Conventional and Advanced MRS Protocols
Thirteen metabolites passed the 50% CRLB criteria in both MRS protocols, although with statistically significant differences in concentrations among protocols (Fig. 5) . Concentrations of metabolites other than the three main singlet resonances (tCho, tCr, and tNAA), ascorbate, sIns, and lactate were significantly different between the conventional and advanced protocols. In particular, concentrations of J-coupled metabolites (e.g., Glu, Gln, Ins, GSH, and GABA) were higher with the conventional protocol. To investigate whether these differences might result from using optimized versus default LCModel parameters and the choice of simulated versus measured MM, three fitting approaches were compared using the sLASER data as a result of their higher quality relative to the PRESS data sets (Supporting Fig.  S2 ). This comparison showed that concentrations were largely comparable when using the default versus optimized LCModel parameters, whereas statistically significant differences were found for most metabolites between simulated versus measured MM. These data in particular indicated that the use of simulated versus measured MM can introduce biases in the concentrations of the weakly represented metabolites such as GABA, Gln, and GSH as a result of underestimation of the MM contributions, particularly in the 2 to 4 ppm range (Supporting Fig. S2 ).
The concentrations of the five major metabolites measured with the advanced protocol were consistent with values recently published in PCC in elderly subjects using short TE STEAM at 7 T (40).
Quantification precision for the five major metabolites was similar between the conventional and advanced protocols, whereas the advanced protocol had a trend for lower CRLB for other metabolites (Fig. 5b) . We investigated whether single-shot phase and frequency corrections of the PRESS data would affect the metabolite concentrations or improve quantification precision (Supporting Information), and found that neither concentrations nor CRLB were different between the PRESS spectra analyzed after single-shot phase and frequency correction versus those analyzed without single-shot corrections (Supporting Fig. S3 ).
Repeatability
Finally, the within-session repeatability of the most reliably quantified metabolites was evaluated with each protocol at different levels of SNR. Metabolites that had a mean CRLB of less than or equal to 20% with both protocols (Fig. 5) were selected for this analysis, as it involved fitting of low SNR spectra, starting with averages of two   FIG. 3 . Overlaid spectra (exponentially line-broadened by 0.5 Hz for display purpose only) acquired from 30 subjects using the conventional and advanced protocols. The upfield region (0-4.1 ppm in the right panel) was appropriately scaled relative to the water residual peak (30-fold multiplication for PRESS spectra, four-fold for sLASER spectra) to show the reproducibility of spectra between subjects.
single-shots. The test-retest CVs were better with MRS data acquired with the advanced compared with the conventional protocol for all metabolites except Glu, and the difference was most significant for low SNR data (averages of two to eight shots) (Fig. 6) .
DISCUSSION
This study showed the feasibility of executing an advanced MRS protocol in the clinical setting with elderly participants and rotating MR technologists. The advanced MRS protocol (sLASER with FM shim) reproducibly generated high-quality MRS data with negligible CSDE and outperformed the conventional protocol (PRESS with vendor-provided shimming routine) with respect to localization accuracy, WS efficiency, spectral resolution, repeatability of metabolite concentrations, and reliable quantification of low-concentration coupled metabolites.
The differences in data quality we observed with the advanced versus the vendor-provided protocol are due to many factors, including sequence optimization, voxelbased calibrations, as well as differences in postprocessing steps, and it was not the goal of our study to what is possible using in-house-developed, advanced MRS technology, on the same standard clinical hardware. In addition, optimization of the standard PRESS sequence would not have affected the intrinsic issue with this sequence at high field, namely the CSDE. A comparison between a vendor-provided STEAM sequence versus an optimized STEAM sequence would have avoided the CSDE issue and provided important insights; however, we chose to focus on protocols that generate full signal intensity for obvious SNR FIG. 6. Mean repeatability CVs for metabolites with mean CRLB less than or equal to 20% as determined from Figure 5 . Error bars represent intersubject standard deviations. *P < 0.01 (two-tailed, paired student's t-test) between conventional versus advanced protocols.
advantages, especially in the elderly brain with appreciable atrophy. Therefore, here we present a practical comparison of a standard versus nonstandard full intensity protocol, with implications on how data quality can be improved for clinical CNS applications of 3T MRS. Important from a practical perspective, the advanced protocol took approximately 2 min longer (Fig. 1) , which can further be reduced by automation (as done in vendor-provided packages) and is deemed justified for the yields in higher data quality.
The main motivation to use a sequence like sLASER at high fields is the CSDE, which can be substantial even at 3 T, especially for refocusing pulses, such that the MRS localization accuracy is compromised, consequently affecting neurochemical quantification. Generally, for VOI located in large cortical areas, CSDE might not be noticeable in the spectra. However, for VOI close to the ventricles or at the edge of the brain, CSDE will be visible in the spectrum (manifested as a distorted spectral pattern or contamination with extracranial lipid signals at approximately 1.2 ppm). The AFP pulses in sLASER reduce the CSDE by approximately six-fold compared with PRESS. In this study, full 3D simulation was implemented to generate accurate basis spectra for reliable spectral fitting of the PRESS data by accounting for the large CSDE (6). However, simulating the PRESS basis spectra for 19 metabolites took approximately 2 months, even though parallel computation in MATLAB was used on at least two Linux machines to reduce computational time. For optimal results, basis sets need to be generated for selected sequence parameters; however, such long computation times are not practical for the clinical setting. Alternatively, these basis spectra could be experimentally measured on phantoms using the identical sequence as used in vivo under normal brain physiological temperature and pH, which might not be feasible in the clinical setting. In contrast, because of negligible CSDE in sLASER, nonlocalized simulation is sufficient to accurately generate the basis spectra and requires a computational time of less than 1 h to simulate all metabolites. Therefore, sLASER provides an advantage for computation time due to ease of generating basis spectra at any TE.
Incorrect flip angles in MRS generally result in low SNR data. In this study, the RF power for the conventional PRESS protocol was determined during the system prescan step on a slice at isocenter, whereas in sLASER the required B 1 field for the RF pulses was obtained in the actual VOI. This, in turn, has resulted in almost half of the PRESS data sets having under-or overestimated RF levels, possibly because of VOI positioning outside the 10-mm slice at the magnet isocenter, where the automatic system RF calibration is conventionally performed, or because of B 1 inhomogeneity within the slice. Several techniques have been proposed that allow RF field adjustment for a specific region at any location (41, 42) . In MRS, however, voxel-based B 1 calibration using the metabolite localization sequence is ideal for accurate RF levels.
One of the critical requirements for obtaining highquality spectra is efficient B 0 shimming in the selected VOI. This is ideally done by adjusting both first-and second-order shim terms using fully automated B 0 field mapping techniques, either based on 3D B 0 mapping or mapping along projections, whereas the precision of the field mapping depends on the spatial resolution and evolution time. We obtained significantly narrower spectral linewidths with FM versus the vendor-provided advanced 3D shim routine, because of the spatial resolution used in acquiring the B 0 maps or projections: Advanced 3D shim uses a fixed resolution of approximately 8 mm in each direction, whereas in this study the FM shim had 1.2 mm resolution. Therefore, a typical voxel dimension of 20 mm will contain three pixels with advanced 3D shim compared with 17 pixels with FM, reducing the precision of the calculated shims with advanced 3D shim. Note that all measurements in this study were done on a VB17 platform. In the latest Siemens software update (i.e., syngo VD and VE platforms), the spatial resolution can be changed based on specific regions of interest, likely improving the shimming results with the vendor-provided shim routine.
The comparative analyses showed systematic differences between concentrations obtained with the conventional versus the advanced protocols, and in particular suggested that some low-concentration J-coupled metabolites are overestimated with simulated MM, consistent with a previous study (43) . Performing single-shot phase and frequency corrections of the conventional PRESS data did not affect the metabolite concentrations or CRLB (Supporting Fig. S3 ), suggesting that single-shot frequency and phase corrections of broad spectra (water linewidth of 10.5 6 3.7 Hz for the PRESS data) will not improve the spectral quality and quantification precision. Alternatively, the reason for no improvement in CRLB with single-shot corrections of PRESS data in our study may have been that we studied a healthy and relatively cooperative cohort. Improvements in linewidth and CRLB in conventional MRS data with single-shot correction are likely in less cooperative clinical cohorts with higher amounts of motion. Note, however, that the single-shot frequency and phase correction is only acceptable for motion that does not substantially change the tissue content of the voxel. For larger ( cm level) motions, recently implemented real-time voxel tracking methods (44, 45) will be necessary to acquire both conventional and advanced MRS data with accurate localization.
We observed higher repeatability of metabolite quantification with the advanced than the conventional protocol, in particular for low SNR data, for the major metabolites except Glu (Fig. 6 ). For Glu, both protocols provided equivalent repeatability, possibly because of the overestimated Glu concentrations with PRESS. At low SNR, most significant differences in repeatability between the conventional and advanced protocols were observed for Ins and sIns. This suggests that the advanced protocol might be more sensitive to changes in preclinical Alzheimer's disease and mild cognitive impairment caused by Alzheimer's disease (46) , in which elevated Ins is a very early marker of neurodegeneration, even before detectable amyloid pathology (47) .
The advanced MRS protocol required manual B 1 calibrations and the use of the nonstandard FM shimming routine. When the technologists were surveyed regarding the most challenging steps in the protocol, they ranked voxel-based B 1 and B 0 calibrations highly. Therefore, there is a need to automate these calibration steps to simplify use of the advanced protocol in the clinical setting. The technologists further emphasized that the transfer of raw data from the scanner for off-site analysis was challenging in the clinical workflow, suggesting that onsite data analysis would be beneficial in the future. Such automation of data acquisition and analysis will likely be even more critical for sites that do not have MR technologists with similar levels of MRI and MRS expertise as those who participated in the current study.
One limitation of the current study is that although the healthy elderly cohort presented a good test case for comparison of advanced versus conventional MRS protocols, the proposed methodology needs to be further tested in neurological disease cohorts. Specifically, studies with clinical cohorts with higher levels of motion, atrophy, or lipids that may occur in neurodegenerative and oncological diseases are needed to fully evaluate the performance of the advanced protocol. The protocol is expected to provide further advantages in cohorts with higher levels of motion and atrophy, as the single-shot correction minimizes signal loss as a result of small phase/frequency shifts. Presence of lipids in the VOI is not expected to affect the performance of the protocol, as we have seen with the falx cerebri lipid peak in our healthy elderly cohort. The protocol is expected to minimize lipid contributions from outside the VOI (e.g., in voxels close to the skull) as a result of the sharper profiles of the adiabatic RF pulses, and thereby even allow quantification of within-voxel lipids in conditions with lipid accumulation, as we have shown previously (48). Finally, although LCModel quantification is not FDA approved for clinical diagnoses, results obtained from both MR vendor-provided packages (metabolite intensity ratios) and from the LCModel have been reported in the clinical setting (49) . Importantly, several other MRS quantification packages are freely available, such as QUEST in jMRUI (50), TARQUIN (51) and VeSPA (52) , and it will be beneficial to further develop and integrate any of these analysis packages in the postprocessing pipelines on clinical scanners for streamlined quantification of MRS data.
CONCLUSIONS
In summary, this study showed that excellent-quality MR spectra can be obtained using an advanced MRS acquisition protocol in the clinical setting. The advanced protocol outperforms the conventional MRS protocol in localization accuracy (minimal CSDE), spectral quality, and reliable quantification of low-concentration J-coupled metabolites. These findings warrant further automation and standardization of the advanced protocol for improved MRS data quality and reproducibility in clinical applications and multisite clinical research studies.
In conclusion, this study shows that the translation of an advanced MRS protocol into the clinical setting is feasible using standard MR hardware at 3 T.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the online version of this article. Fig. S1 . Comparison of measured reference voltages between the advanced (sLASER) and conventional (PRESS) protocols. For each subject, voltages used with PRESS protocol are plotted versus the voltage used with sLASER. Sixteen of 30 subjects had identical values between PRESS and sLASER protocols; these points lie on the identity line (red line), and 14 subjects had either under-or overestimated levels with PRESS relative to voxel-based sLASER calibration. Fig. S2 . Left panel: Mean metabolite concentrations of sLASER spectra (TE 5 28 ms, 64 averages) quantified using the three different LCModel approaches. Note that GABA was not reported in the "Measured MMLCModel approach 2," as it did not pass the criteria (CRLBs 50% from at least half of the spectra). Error bars represent intersubject standard deviations. *P < 0.01 between Simulated MM -LCModel approach 1 versus Measured MM -LCModel approach 2 and ᭜ P < 0.01 between Simulated MM -LCModel approach 2 versus Measured MM -LCModel approach 2 (two-tailed, paired student's t-test). Right panel: Simulated and measured MM spectra (between-subject mean 6 standard deviation) plotted together with their respective spline baseline obtained with the three approaches. Fig. S3 . Mean metabolite concentrations and CRLBs with PRESS obtained using the routine procedure in the clinical setting (PRESS) and advanced research analysis procedure (PRESS processed). No differences in concentration and CRLBs were observed, most likely because of the broad spectral linewidth.
